

Review



**Cite this article:** Wilkinson HN, Hardman MJ. 2020 Wound healing: cellular mechanisms and pathological outcomes. *Open Biol.* **10**: 200223. <http://dx.doi.org/10.1098/rsob.200223>

Received: 22 July 2020  
Accepted: 8 September 2020

**Subject Area:**  
cellular biology

**Keywords:**  
wound healing, chronic wounds, tissue repair, diabetes, ageing, skin

**Author for correspondence:**  
Holly N. Wilkinson  
e-mail: [h.n.wilkinson@hull.ac.uk](mailto:h.n.wilkinson@hull.ac.uk)

# Wound healing: cellular mechanisms and pathological outcomes

Holly N. Wilkinson and Matthew J. Hardman

Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, The University of Hull, Hull HU6 7RX, United Kingdom

HNW, 0000-0002-8453-7264


Wound healing is a complex, dynamic process supported by a myriad of cellular events that must be tightly coordinated to efficiently repair damaged tissue. Derangement in wound-linked cellular behaviours, as occurs with diabetes and ageing, can lead to healing impairment and the formation of chronic, non-healing wounds. These wounds are a significant socioeconomic burden due to their high prevalence and recurrence. Thus, there is an urgent requirement for the improved biological and clinical understanding of the mechanisms that underpin wound repair. Here, we review the cellular basis of tissue repair and discuss how current and emerging understanding of wound pathology could inform future development of efficacious wound therapies.

## 1. Introduction

Millennia of evolution have created our skin, a highly adaptive, multifunctional organ that protects us from a daily onslaught of chemical, physical and ultraviolet radiation challenge. This harsh external environment often results in injury to the skin, and it will therefore come as no surprise that our skin possesses sophisticated reparative processes that allow it to heal quickly and efficiently. Despite considerable innate reparative ability, multiple cellular aspects of an individual's injury response can become attenuated, compromising wound closure. This attenuation is most often a result of pathological systemic changes, such as those associated with advanced age or uncontrolled diabetes. Indeed, age and diabetes are primary risk factors for developing a chronic wound (i.e. a wound that takes longer than 12 weeks to heal). Unfortunately, these chronic wounds (primarily venous ulcers, pressure sores and diabetic foot ulcers) are a major area of unmet clinical need, increasing significantly on a global scale [1]. Here, we discuss the current understanding of skin repair and illustrate impaired cellular behaviours that underpin chronic wound healing pathology. Application of emerging research technologies will be essential in further elucidating the underlying cellular and molecular basis of acute and pathological repair.

## 2. Cellular aspects of acute wound repair

Our skin is specialized to interface with the external environment and provides a variety of important homeostatic functions, from regulating thermostability to sensing extrinsic stimuli. Crucially, the skin acts as a primary defence barrier, preventing desiccation and mechanical, chemical, thermal and photic damage to internal structures [2]. This defence extends to a sophisticated immune barrier response that protects against pathogenic infection, while supporting commensal microorganisms via an elegantly adapted host–microbiota axis [3]. The skin has also evolved efficient and rapid mechanisms to close breaches to its barrier in a process collectively known as the wound healing response. Wound repair is classically simplified into four main phases: haemostasis, inflammation, proliferation and dermal remodelling [4], which result in architectural and physiological



**Figure 1.** The stages of wound repair and their major cellular components. Wound repair begins with haemostasis, where a platelet plug prevents blood loss and a preliminary fibrin matrix is formed. Inflammation then ensues to remove debris and prevent infection, commencing with neutrophil influx, which is promoted by histamine release from mast cells. Monocytes arrive later and differentiate into tissue macrophages to clear remaining cell debris and neutrophils. During the proliferative phase, keratinocytes migrate to close the wound gap, blood vessels reform through angiogenesis, and fibroblasts replace the initial fibrin clot with granulation tissue. Macrophages and regulatory T cells (Tregs) are also vital for this stage of healing. Finally, the deposited matrix is remodelled further by fibroblasts, blood vessels regress and myofibroblasts cause overall wound contraction.

restoration following damage (figure 1). The following sections describe these stages in detail.

### 2.1. Haemostasis

Immediately after injury, damaged blood vessels rapidly contract and a blood clot forms preventing exsanguination from vascular damage [5]. Platelets, principle contributors to haemostasis and coagulation, are activated when they encounter the vascular subendothelial matrix. Platelet receptors (e.g. glycoprotein VI) interact with extracellular matrix (ECM) proteins (e.g. fibronectin, collagen and von Willebrand factor), promoting adherence to the blood vessel wall. Thrombin subsequently triggers platelet activation, inducing a conformational change, and release of alpha and dense granules containing bioactive molecules which reinforce coagulation (reviewed in [6]). An insoluble clot (eschar) of fibrin, fibronectin, vitronectin and thrombospondin forms [7], primarily serving to plug the wound and prevent bleeding. The eschar also fulfils a number of secondary functions, including shielding against bacterial invasion, providing a scaffold for incoming immune cells and harbouring a reservoir of cytokines and growth factors to guide the behaviour of wound cells in early repair [8].

Platelets are crucial in the recruitment of immune cells to the injury site, by either directly capturing immune cells in the eschar, or by releasing a secretome of chemokine

attractants upon degranulation [6]. In fact, the platelet secretome also contains growth factors that stimulate resident skin cells, including fibroblasts and keratinocytes [9]. As the most abundant cell type during early repair, platelets play an active role in the early inhibition of bacterial infection. They express a number of toll-like receptors (TLRs) [10,11], which regulate the production of antimicrobial peptides [12]. Once a sufficient clot has formed, the coagulation process is switched off, preventing excessive thrombosis. Here, platelet aggregation is inhibited by prostacyclin, thrombin inhibited by antithrombin III, and coagulation factors V and VII degraded by activated protein C [13]. At the same time, the injured vessel wall is repaired by smooth muscle cells and endothelial cells that proliferate in response to released platelet-derived growth factor (PDGF) [14]. Endothelial progenitors are also recruited to aid this process as mature endothelial cells show limited proliferative capacity [15].

### 2.2. Inflammation

Innate inflammation evolved as the primary defence against pathogenic wound invasion. This immune response is initiated by injury-induced signals; damage-associated molecular patterns (DAMPs) released by necrotic cells and damaged tissue, and pathogen-associated molecular patterns (PAMPs) from bacterial components. These PAMPs and DAMPs activate resident immune cells, such as mast cells, Langerhans cells,

T cells and macrophages, by binding pattern recognition receptors to elicit downstream inflammatory pathways [16]. A subsequent release of pro-inflammatory cytokines and chemokines attracts circulating leucocytes to the site of injury (reviewed in [17]). Pro-inflammatory molecules also stimulate vasodilatation, which, along with the expression of endothelial cell adhesion molecules, such as selectins, facilitates neutrophil and monocyte adhesion and diapedesis [18]. In fact, the importance of selectins in immune cell recruitment has been clearly demonstrated, with genetic [19] and pharmacological [20] blockade of E- and P-selectin significantly impairing both immune cell infiltration and wound healing.

Neutrophils, which arrive early after injury, are recruited into the wound from damaged vessels, attracted by chemoattractants, including interleukin 1 (IL-1), tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) and bacterial endotoxins, such as lipopolysaccharide (LPS) [21]. In response to pro-inflammatory signals, and activation of inflammatory signalling pathways (e.g. NF- $\kappa$ B [21]), neutrophils (and other wound cells) release their own cytokines. Neutrophils remove necrotic tissue and pathogens via phagocytosis and the release of reactive oxygen species (ROS), antimicrobial peptides, eicosanoids and proteolytic enzymes [22]. They also trap and kill pathogens in an extruded web of DNA coated with antimicrobial peptides and cytotoxic histones, termed extracellular traps [23].

The inflammatory response is complex, modulated by a multitude host of intrinsic and extrinsic factors. Uncontrolled and excessive inflammation promotes tissue injury and delays healing (as in diabetic mice [24]). However, insufficient immune cell recruitment, for example in TLR3 knockout mice, also hinders repair [25]. Thus, immune cell responses must be situational, increasing to respond appropriately to infection, yet clearing effectively to allow wound resolution. In the absence of infection, wound neutrophils decline within a few days of injury onset [26]. Most neutrophils are extruded from the wound site as they adhere to the fibrin scab, while others are removed by innate clearance mechanisms such as macrophage efferocytosis [17]. Remaining neutrophils are cleared by apoptosis, necrosis or phagocytosis, or may leave inflamed tissue and return to the circulation through reverse transendothelial migration, as observed in zebrafish [27], mice [28] and human neutrophils *in vitro* [29].

Circulating monocytes enter the wound tissue where, in response to the local milieu, they differentiate into macrophages. Although it is generally suggested that macrophages are recruited following neutrophils, an initial wave of monocytes has been observed entering the wound simultaneously with neutrophils [30]. Macrophages are master effector cells in tissue repair, displaying both versatility and high plasticity (reviewed in [31]). They reach peak wound infiltration 72 h after injury in mice and 7 days post-injury in humans [32]. Like neutrophils, macrophages engulf necrotic cellular debris and pathogenic material through evolutionarily conserved receptors, but also exhibit differential behaviours and morphological changes in response to cytokines [33].

Wound macrophages are traditionally separated into two main subsets: M1-stimulated and M2-stimulated. However, this dichotomous classification has become outdated, with both human [34] and murine [35] macrophages now known to show diverse transcriptional and phenotypic responses to different stimuli (reviewed in [36]). Hence, the macrophage repertoire should be viewed as a spectrum of phenotypes governed by tissue status and environmental signals [37,38]. For simplicity,

we will herein refer to classically activated (pro-inflammatory) and alternatively activated (anti-inflammatory) groups.

Classically activated macrophages are induced by pro-inflammatory stimuli, such as LPS and interferon- $\gamma$  (IFN- $\gamma$ ), and promote inflammation by releasing ROS, inflammatory cytokines (e.g. IL-1, IL-6 and TNF- $\alpha$ ) and growth factors (e.g. vascular endothelial growth factor, VEGF and PDGF). These macrophages phagocytose apoptotic neutrophils, replacing them as the main inflammatory mediator [8]. Later stages of inflammation are characterized by a transition to alternative activation, which occurs through neo-differentiation of newly recruited monocytes, or via switching of existing macrophages *in situ* to an anti-inflammatory phenotype. Although not widely characterized, this phenotypic switch can be stimulated by environmental changes in cytokines [39] and efferocytosis [40]. It may additionally be driven by miRNAs [31], transcription factors [41], and modulation of pro-inflammatory and anti-inflammatory receptors [41,42].

Alternatively activated macrophages express pro-resolatory cytokines (IL-4, IL-10, IL-13 [43,44]) and arginase, a key factor for effective wound repair [45]. Anti-inflammatory macrophages also release a myriad of growth factors to promote re-epithelialization, fibroplasia [8] and angiogenesis [46]. More recently, macrophages have been shown to be crucial in the stabilization and remodelling of blood vessels in mice and fish [47].

The importance of macrophages is further demonstrated in selective ablation studies, where *Cd11b*-specific deletion of macrophages leads to delayed wound repair and increased inflammation [48]. Similarly, inducible knockdown of macrophages during early healing caused delayed re-epithelialization, angiogenesis and granulation tissue formation, while knockdown of macrophages mid-way through healing led to endothelial cell damage, severe haemorrhage and immature granulation [49]. Thus, the collective behaviours of macrophages promote scavenging of debris, bacteria and pro-inflammatory cells, while also stimulating reparative processes to allow effective wound resolution.

The overwhelming presence of neutrophils and macrophages in wounds has potentially masked the importance of other myeloid cells in wound repair. However, recent studies have revealed that resident T cells are critical for the early injury response, while circulating T cells are recruited to resolve inflammation [50]. Indeed, aged and diabetic mice show reduced resident dendritic epidermal T cells and a delayed healing phenotype, whereas subcutaneous administration of dendritic epidermal T cells can restore healing [51,52]. Moreover, the removal of anti-inflammatory regulatory T cells delays tissue repair in mice [50]. Mast cells also play a role in wounds, releasing histamine to aid neutrophil recruitment during early inflammation [53].

### 2.3. Proliferation

The proliferative phase of healing is characterized by extensive activation of keratinocytes, fibroblasts, macrophages and endothelial cells to orchestrate wound closure, matrix deposition and angiogenesis. As early as 12 h post-injury, keratinocytes are activated by changes in mechanical tension and electrical gradients, and exposure to hydrogen peroxide, pathogens, growth factors and cytokines [54]. This activation causes keratinocytes at the wound edge to undergo partial epithelial–mesenchymal transition, where they develop a



more invasive and migratory phenotype [55]. Front-to-rear polarity replaces top-to-bottom polarity, allowing the leading-edge keratinocytes to migrate laterally across the wound to reform the epidermal layer, a process termed re-epithelialization [56]. Keratinocytes behind the leading edge modulate their cell adhesion via PCK $\alpha$ -mediated changes in desmosome adhesiveness [57] and Eph-mediated changes in adherens junctions [58], allowing them to rearrange their order with the migrating epithelial sheet [54]. Keratinocytes in the neo-epidermis release matrix metalloproteinases (MMPs) to aid their path of migration, while laying down new ECM proteins to reconstitute the basement membrane [59].

Hair follicle stem cells are induced to proliferate, with progeny epidermal cells streaming out of the follicle to meet the cellular demand required to resurface the wound [60]. These cells sprout from damaged appendages in shallow wounds, or arrive from the epidermal edge in full-thickness wounds. Only specific stem cell compartments are activated or recruited to the re-epithelialization process [61]. For example, Krt15+ve [62] and Krt19+ve [63] bulge region stem cells appear dispensable for re-epithelialization, while Lgr5- and Lgr6-expressing cells from the follicle and inter-follicular epidermis respond to wound cues, contributing to re-epithelialization [64]. A key characteristic of full-thickness wounds in mice is that appendages, including follicles, are absent from re-formed scar tissue [2]. However, under specific circumstances wound-induced follicle neo-genesis can occur, seemingly via re-activation of developmental Wnt and Shh signalling [60].

Keratinocytes negotiate through debris and necrotic tissue of the wound bed through their interactions with structural proteins of the preliminary matrix via integrin receptors [65]. MMPs, particularly MMP-1 and MMP-9, are vital for keratinocyte migration as they aid integrin receptor dissociation [56]. The production of other proteases, such as plasmin, further facilitates keratinocyte migration by degrading the provisional fibrin-rich wound bed [59]. When keratinocytes from opposing edges meet, migration terminates (via an undetermined mechanism), a thin epithelial layer is established and keratinocytes form new adhesions to the underlying matrix. Keratinocytes then fully reform the basement membrane and undergo terminal differentiation, to stratify and regenerate the epidermis [32].

Fibroblasts are the main cell type responsible for replacing the provisional fibrin-rich matrix with a more substantial granulation tissue. Resident and mesenchymally derived fibroblasts respond to a milieu of signalling molecules from platelets, endothelial cells and macrophages, including transforming growth factor (TGF- $\beta$ ) and PDGF. These signals direct fibroblasts to either become pro-fibrotic, laying down ECM proteins, or differentiate into myofibroblasts which drive wound contraction [55]. It is important to note that this is again a simplification, as in reality fibroblasts exhibit functional diversity, assisting dermal repair in different ways. In a seminal study Driskell *et al.* [66] demonstrated that skin fibroblasts originate from two distinct lineages, where the upper lineage aids re-epithelialization while the lower lineage contributes to ECM deposition. Recent findings have further challenged conventional understanding of wound fibroblast origin, showing that two-thirds of granulation tissue fibroblasts are actually myeloid derived [67], and are thus likely to stem from wound macrophages. Fibroblasts degrade the provisional matrix by producing MMPs and

replace it with a granulation tissue rich in fibronectin, immature collagens and proteoglycans [68]. This granulation tissue acts as a scaffold for the migration and differentiation of wound cells, supporting both the formation of new blood vessels and the deposition of mature ECM.

New blood vessels are created during the process of angiogenesis to meet the metabolic demands of the highly proliferative healing tissue. Angiogenesis is triggered by hypoxia, which in turn drives the expression of hypoxia-inducible factors (HIFs) and cyclooxygenase 2, and subsequent release of VEGF and other factors [69]. In response to these changes, microvascular endothelial cells proliferate and migrate into the wound bed, sprouting new vessels that fuse with others to develop stable, tubular networks [70]. VEGF prevents endothelial cell apoptosis by upregulating anti-apoptotic proteins such as BCL-2 [71], while the fibrin matrix promotes angiogenesis by triggering phenotypic changes in endothelial cells to stimulate their migration [72].

Macrophages play a significant role in angiogenesis by aiding microvascular endothelial cell behaviours. They produce proteases such as MMPs to degrade the dense fibrin network and chemotactic factors (e.g. TNF- $\alpha$ , VEGF and TGF- $\beta$ ) to drive endothelial migration (reviewed in [73]). Willenborg *et al.* [74] demonstrated the importance of macrophage-derived factors in angiogenesis, where myeloid-specific deletion of VEGF-A reduced capillary formation in murine wounds. Macrophages also participate in the remodelling of new vasculature, by guiding vessel tips together [75], phagocytosing superfluous vessels [47,76] and dampening the angiogenic response to prevent excessive vascularization [77].

The skin houses a dense network of sensory and autonomous nerve fibres which allow sensation and movement. Nerve fibre regeneration is therefore essential following injury. Despite the principle role of diabetic skin denervation in wound pathogenesis (reviewed in [78]), wound innervation *per se* remains an understudied area. Neuropeptides, such as substance P, are known to be released from sprouting neurons and immune cells during repair, influencing diverse cellular processes (e.g. proliferation and angiogenesis [79,80]). Notably, substance P is reduced in delayed healing in diabetic wounds, where topical restoration restores healing [81,82] and contributes to nerve regeneration [83]. Wound-activated glial cells are also an important component of the repair response, shown to express factors important for chemotaxis, while the loss of glial cells delays healing in wild-type mice [84]. These and other studies suggest that innervation plays a substantial role in effective repair.

## 2.4. Matrix remodelling

Remodelling of the ECM spans the entire injury response, beginning with the initial deposition of a fibrin clot, and ending several years later with the formation of a mature, type I collagen-rich scar [55]. Fibroblasts are the major cell type responsible for wound ECM remodelling, replacing the initial fibrin clot with hyaluronan, fibronectin and proteoglycans, and forming mature collagen fibrils later in repair [85]. Proteoglycans aid construction of mature, cross-linked collagen fibrils and act as a conduit for cell migration [86]. The collagen composition of uninjured adult skin is approximately 80% collagen type I: 10% collagen type III. By contrast, granulation tissue predominantly comprises of the embryo-associated collagen type III (approx. 30%), with

only 10% collagen type I [87]. As healing progresses, collagen type III is replaced by collagen type I, directly increasing the tensile strength of the forming scar [88]. The integrity and architecture of scar ECM never fully returns to that of unwounded skin. Collagen fibrils in scar dermis adopt large parallel bundles, while in uninjured skin fibrils adopt a basket weave orientation. Thus, wound scar tissue confers only up to 80% of pre-wounding strength post-injury [87,89].

These sequential changes in the ECM require a fine balance between collagen degradation and synthesis, achieved through temporal regulation of key MMPs. These collagenases, expressed by anti-inflammatory macrophages, fibroblasts and keratinocytes, cleave native helical collagens throughout repair [85]. Elastin, another key dermal ECM component, must reform elastic fibres to retain skin elasticity. Interestingly, the degradation of normal dermal matrix causes the release of elastin fragments, or elastokines, which act as signalling molecules [90]. Elastin is formed from its precursor, tropoelastin, and early in healing shows the aberrant arrangement. In fact, mature elastin fibres are often only apparent in scar tissue many months after injury [91,92].

Heightened expression of TGF- $\beta$  and mechanical tension stimulate myofibroblast differentiation *in vivo* and *in vitro* [93]. Myofibroblasts are characterized by an abundance of alpha-smooth muscle actin ( $\alpha$ -SMA), associated with an ability to generate strong contractile forces and focal adhesions [85]. Curiously, mice lacking the gene encoding  $\alpha$ -SMA, *Acta2*, heal normally with no obvious change in fibroblast contraction [94]. This apparent redundancy, with compensation by other microfilaments, highlights the importance of wound contraction. Myofibroblast contraction is facilitated by pseudopodial extensions that allow cytoplasmic actin to bind to fibronectin in the matrix scaffold [55]. Myofibroblasts adhere to one another via desmosomes, binding to matrix fibrils and drawing the matrix together by a process termed contracture [95]. The wound healing response abates when macrophages, endothelial cells and fibroblasts undergo apoptosis or exit the injury site, leaving a scar [96].

### 3. When healing fails—factors influencing chronic wound healing

Acute wound repair is a highly dynamic cascade of cellular signalling and behavioural events that ensures rapid closure of the skin barrier. High levels of redundancy and compensatory mechanisms ensure that small alterations to this response seldom cause problems in healing wounds [97]. For example, the ablation of specific subsets of hair follicle stem cells [63], MMPs [98], fibroblast growth factors [99], TGF- $\alpha$  [100] and VEGFR2 [101] each individually fail to significantly impair wound closure. However, like any biological process, sufficient perturbation to the system leads to aberrations, which in the case of wounds manifest as excessive scarring at one extreme or failure to heal entirely at the other. Wounds that fail to heal (defined as generally remaining unhealed after 12 weeks) are termed chronic wounds. They primarily affect the elderly and diabetic, are highly prevalent and a major socio-economic burden [102,103]. More effective clinical management would prevent a proportion of these wounds [104], yet many remain refractory to current treatment, highlighting the need to better understand the cellular basis of wound pathology in order to develop therapeutically viable treatments.

Susceptibility to injury remains understudied. We know that the skin of aged and diabetic mammals is more predisposed to injury, as it undergoes atrophy, with altered skin barrier and reduced hydration [105,106]. Both ageing and diabetes lead to the gradual loss of dermal matrix, with corresponding changes in tissue mechanics, loss of resilience and increased susceptibility to friction damage [107,108]. Once an injury occurs, a range of molecular and cellular perturbations contribute to overall healing impairment. One factor widely implicated in aged and diabetic wound pathology is cellular senescence (reviewed in [109]). Mitotic cells become senescent and non-proliferative in response to a host of intrinsic and extrinsic factors. Senescent cells acquire a hypersecretory phenotype, producing a secretome rich in pro-inflammatory cytokines and tissue-degrading proteases (reviewed in [110]). The chronic wound environment is the perfect platform for senescent cell induction due to the high levels of inflammation and oxidative stress [111]. Indeed, we recently demonstrated that high senescent cell burden contributes to wound pathology, where blockade of the proposed senescence receptor, CXCR2, dampens macrophage senescence and improves healing in diabetic mice [112].

A key contributor to wound pathology is excessive inflammation, which perpetuates chronicity through the continued destruction of wound tissue. Chronic wounds are characterized by high numbers of Langerhans cells [113,114], neutrophils [115], pro-inflammatory macrophages [116,117] and proteases [118–120], linked to clinical ulcer severity [121]. Along with elevated infiltration of specific immune cell subsets [122], pathological immune cell function is perturbed and collectively contributes to poor healing. Here, neutrophils are excessively primed to produce neutrophil extracellular traps, which are cytotoxic [123] and delay wound healing [124]. In diabetic mice, neutrophils are more resistant to apoptosis, and less effectively cleared by macrophages [125], furthering their excessive presence in pathological wounds. Diabetic macrophages also exhibit defective efferocytosis of apoptotic cells [126], impaired phagocytosis of bacteria [127,128] and reduced ability to polarize to an anti-inflammatory state [129]. Interestingly, even prior to ulceration, the skin of diabetic humans and mice exhibits higher numbers of mast cells and macrophages primed to the pro-inflammatory state [130]. By contrast, T cell receptor diversity [131] and the number of CD4+ T cells [116,131] are reduced in diabetic foot ulcers. Together, these aberrant features of chronic wound immune cells not only prevent the shift from inflammation to resolution, but greatly increase vulnerability to infection. Heightened inflammation may also persist due to chronic wound infection, thus maintaining the wound in a continuous cycle of infection, inflammation and inadequate repair.

Cellular impairment is not only restricted to inflammation, but also extends to re-epithelialization and dermal remodelling. Non-healing diabetic foot ulcers are typically characterized by an epidermal wound edge that is hyperkeratotic and parakeratotic [132]. Keratinocytes at the chronic wound edge show abnormal nuclear presence of  $\beta$ -catenin and elevated *c-myc*, which directly delays migration *in vitro* [132] and prevents healing in mice [133]. Ulcer wound edge epidermis additionally displays the misexpression of a number of cell cycle, differentiation and desmosomal markers [134], impaired growth factor receptor signalling [135], and lacks hair follicles [136]. This aberrant activation phenotype, with seemingly uncontrolled wound edge proliferation,

is thought to directly inhibit keratinocyte-mediated chronic wound closure.

At the same time, dermal reconstitution is significantly inhibited by the high wound protease levels, which not only break down dermal ECM components, but also degrade growth factors (e.g. VEGF and TGF- $\beta$  [137,138]) and cytokines (e.g. TNF- $\alpha$  [139]). Chronic wound fibroblasts are highly senescent, further compromising ECM deposition [140–142], and are unresponsive to ECM-stimulating factors such as TGF- $\beta$  [143,144]. Interestingly, we recently demonstrated that deficiency in wound iron may underpin reduced ECM deposition in diabetic mice, as iron loading of fibroblasts directly stimulates ECM deposition and remodelling [145]. Macrophages are key to this reparative response, where iron sequestration causes alternatively activated macrophages to produce ECM-stimulating factors [146]. Note that disparities exist in the reported role(s) of iron in wound repair. Sindrilaru *et al.* [117] suggest that iron deposition caused delayed healing in diabetic foot ulcers, promoting an unrestrained M1-like macrophage phenotype, increased oxidative stress and senescence. Similarly, others have shown that the iron chelator, deferoxamine, improves wound healing in pressure ulcers of diabetic [147] and aged [148] mice. Thus, the cellular effects of iron are probably context-dependent and wound-type-specific, exacerbating tissue damage in an already pro-inflammatory environment, while promoting alternatively activated macrophage- and fibroblast-mediated wound resolution in late-stage repair.

Sustained hyperglycaemia in diabetes directly contributes to defective healing, compromising leucocyte function [149], inducing cellular senescence [150] and causing non-enzymatic glycation of ECM and the formation of advanced glycation end products (AGEs) [151]. AGEs not only alter the dermal structural architecture, but also trigger inflammation and ROS via their receptor, RAGE [152]. These effects impair neovascularization, in part by preventing HIF-1 $\alpha$  transactivation and subsequent upregulation of VEGF and stromal-derived factor 1 (SDF-1) [153,154]. At the macroscopic level, uncontrolled diabetes causes long-term damage to the microvasculature, which results in local tissue hypoxia, arterial vasculopathy and/or lower limb neuropathy—all extreme risk factors for chronic wound development [155].

In diabetes, stem cell populations that would usually participate in vascularization are depleted (e.g. bone marrow [156]) or show impaired neovascular potential (in adipose tissue [157]). A reduction in SDF-1, which aids recruitment of endothelial progenitor cells to wounds, is also observed, while topical administration of SDF-1 accelerates diabetic wound repair [158]. Slowing AGE formation in diabetic mice improves the neovascular potential of bone marrow progenitors [159], confirming functional relevance and further demonstrating the important contribution of uncontrolled diabetes in wound pathology.

It is crucial to note that the causes of delayed healing, while simplified above, are often multifactorial and complex. Wound chronicity is influenced by local and systemic defects [160], along with imbalances in hormones, cytokines and growth factors (e.g. reduced PDGF [161]). However, in recent years, the presence and persistence of wound infection has been widely discussed as a major contributor to chronicity [162]. Indeed, high abundance of common wound pathogens, such as *Staphylococcus aureus* and *Pseudomonas aeruginosa*, is reported in chronic wounds [163,164], with a

wound's microbial profile strongly linked to healing outcome [165]. These pathogens often develop into polymicrobial aggregates (biofilms) encapsulated in a protective matrix of extracellular polymeric substances that confers resistant to traditional antibiotics and host defences (reviewed in [166]).


The microbiome profiles of aged and diabetic skin differ considerably from their young and non-diabetic counterparts, in each case displaying reduced  $\alpha$ -diversity [167,168]. Although critical wound colonization occurs as a result of inadequate immune cell function, poor perfusion and the presence of a persistent open wound, it is likely (though yet to be proven) that aged and diabetic skin is intrinsically predisposed to infection by an altered microbiome. Diabetic wounds also show altered expression of pattern recognition receptors responsible for eliciting a host response, which may link to poor healing [169]. Interestingly, knockout of the pattern recognition receptor, Nod2, impaired wound closure [170] and altered the skin microbiome [171] of mice. Curiously, wild-type mice cross-fostered into Nod2-/- litters adopted an altered microbiome and acquired a delayed healing phenotype [171], therefore directly demonstrating the impact of skin microbiota dysbiosis on repair. Key factors in chronic wound pathology are summarized in figure 2.

#### 4. Translational techniques to enhance clinical understanding of wounds

Our knowledge of the mechanisms underlying chronic wound healing is constantly improving, largely due to the development and refinement of wound models and diagnostic tools. For example, until the advent of sequencing technologies, wound bacterial profiling was restricted to simple culture methods, limiting speciation to only organisms capable of expansion in culture. Further analysis was then required to gather complete diagnostic information about a clinical isolate (reviewed in [172]). The emergence of short-read 16S sequencing provided new insight into clinical bacterial communities, but bacterial identification was limited to genus level based on inference from sequence homology [173], with little information about their virulence or clinical significance. Novel genomic technologies are now emerging to allow rapid molecular identification of microorganisms to the sub-species level. Simultaneous characterization of antibiotic resistance and virulence profiles [173,174] provides unprecedented insight into the role of bacterial, fungal and viral ecosystems in wound pathology. Combining these techniques with host genomic, metabolomic and proteomic approaches promises to deliver in depth understanding of the myriad of factors influencing wound repair, while ultimately facilitating a true 'personalised medicine' approach to clinical wound management.

Historically, wound studies have relied on the use of *in vivo* models to address the complexity of the multifactorial wound response. However, it is widely accepted that between-species differences have hindered translational wound research efforts. We are now moving towards the development of more dynamic *in vitro* approaches, such as three-dimensional skin equivalents [175], allowing closer modelling of native human cell behaviours, and moving away from artificial single-cell monolayer culture. While cultured three-dimensional skin equivalents still lack many skin features, such as glands, immune cells and blood vessels, current research is beginning to address this deficit [176,177]. The development of





**Figure 2.** Factors contributing to chronic wound healing. Chronic wounds become infiltrated with bacteria that exacerbates inflammation. Chronic wound keratinocytes show aberrant activation causing hyperproliferation and impaired migration. A large proportion of chronic wound cells (e.g. macrophages and fibroblasts) become senescent, producing a senescence-associated secretory phenotype (SASP) that perpetuates senescence, triggers reactive oxygen species (ROS) release and heightens inflammation. High amounts of advanced glycation end products (AGEs) also contribute to inflammation and cellular senescence in the wound environment. Together these features cause excessive tissue breakdown and impair cellular functions to prevent normal healing. re-ep = re-epithelialization.

three-dimensional-printed skin equivalents is particularly exciting, offering profound implications in translational research. Indeed, a recently developed vascularized three-dimensional-printed skin model reflected many aspects of native skin, including tissue maturation, and epidermal stratification and stemness [178].

Porcine and human *ex vivo* models are also gaining traction, with the advantage that they provide native skin tissue architecture and the full gamut of resident skin cells to recapitulate important aspects of the human chronic wound healing response [179,180]. *Ex vivo* models are not without their caveats, lacking immune cell infiltration and maintaining viability for a limited time-frame [181]. It is likely that novel culture methods, such as microfluidics [182], will extend tissue viability and allow skin perfusion with biologically relevant factors (and immune cells) to increase the relevance of *ex vivo* wound models.

*In vivo* models are still widely used, with mice favoured for mechanistic studies [183]. The multitude of available transgenic mouse lines (including reporter lines) allows temporal and spatial investigation of the molecular basis of *in vivo* wound healing. Nevertheless, strain- and species-specific differences must be considered, especially when extrapolating conclusions for translational research purposes. Pigs, though used far less frequently, provide a useful translational model with skin that closely resembles that of humans. Wounding in mice involves full-thickness incisions or excisions, yet variability can be introduced between laboratories by the methods used to apply wounds, the analgesics and anaesthetics used, and how the wounds are treated (e.g. splinted, occluded or left to heal by secondary intention [184,185]). Continued efforts to standardize *in vivo* methodology will be essential to increase experimental validity and progress current and future wound research.


An array of pre-clinical delayed healing models are used to better recapitulate human chronic wounds, from pressure

ulcers in mice using magnets [186], to infected wounds in pigs [187]. As those primarily at risk of developing chronic wounds are elderly or diabetic, it follows that the most widely used chronic healing models involve aged and diabetic rodents [188]. Type I and type II diabetes mellitus (T1DM and T2DM) can be modelled in mice. T1DM-mediated delayed healing is commonly stimulated through streptozocin injection [189,190], where timing post-injection is critical to the delayed healing phenotype [192]. Genetically altered mice are used to mimic T2DM through leptin or leptin receptor deficiency. These mice are morbidly obese by 6–8 weeks of age, go on to show hallmarks of T2DM (reviewed in [193]), and display substantially delayed healing versus their non-diabetic, heterozygous littermates [194]. There remains some controversy as to whether delayed healing in diabetic mice is a result of hyperglycaemia, leptin deficiency or obesity [184].

To mimic age-associated healing pathology, mice are wounded at 18 plus months of age (reviewed in [195]). Young ovariectomized mice provide an alternative accelerated ageing model, where surgical removal of the ovaries mimics the human menopause [196]. Here, the loss of circulating sex hormones, particularly 17 $\beta$ -estradiol, produces a delayed healing phenotype that is largely comparable to that of aged mice (reviewed in [197]). Unlike diabetic models, limited to comparison against diabetic wounds, aged models have the advantage that they emulate a more generalized underlying risk factor for all chronic wounds, advanced age [198].

## 5. Current therapies and future opportunities

Wound management begins with an assessment of wound aetiology and a patient-centric approach to managing systemic and lifestyle factors. In the case of diabetic foot ulcers, local management often starts with debridement, the



**Figure 3.** Traditional and novel chronic wound treatments and their major tissue effects. Debridement of infected and necrotic tissue, followed by tailored dressing use, is common in wound treatment, with the aim of reducing microbial burden, dampening inflammation and providing a more suitable environment for healing. Antimicrobial therapies are emerging to disrupt biofilms and selectively remove pathogenic, rather than commensal, organisms. EPS = extracellular polymeric substance. QS = quorum sensing. ABs = antibiotics. Cell therapies such as mesenchymal stem cells (MSCs) can benefit multiple aspects of wound repair. re-ep = re-epithelialization. Finally, targeting chronic wound senescence with senolytics (e.g. metformin or CXCR2 antagonists) may be a viable option to reduce inflammation and promote healing.

removal of necrotic, infected or hyperkeratotic tissue via surgical or less invasive modalities [5,199]. Extracting the chronic tissue back to less affected epidermis, while triggering an acute injury response, is thought to kick-start normal reparative healing pathways [200]. Wounds are then irrigated with saline or antibacterial solution and a tailored dressing is applied [201]. Contemporary dressings contain a myriad of material properties to aid tissue repair and incorporate substances with known pro-healing or antimicrobial effects [202,203]. More advanced solutions are available, including the continually evolving negative pressure wound therapy modality [204]. Despite numerous available treatments, current best practice wound management is almost exclusively aimed at addressing secondary causes of chronicity, while also relying heavily on patient compliance. These two factors result in up to 40% of chronic wounds persisting for many months or years despite extensive treatment [102]. There remains a clinical unmet need to address this shortfall with novel therapies that are financially, physiologically and practically viable for the wound care setting.

A major contributor to chronic wound recalcitrance is persistent, antibiotic-resistant biofilm infection. It is therefore unsurprising that a large proportion of recent wound research has focused on the development of novel antimicrobial and anti-biofilm therapies. Traditional non-antibiotic antimicrobials, such as silver salts, alleviate bacterial burden but are cytotoxic to the host, while modern formulations (e.g. nanoparticles) have lower cytotoxicity and may also promote wound

healing (reviewed in [205]). Emerging antimicrobial treatments that may also show beneficial roles in tissue repair include cold atmospheric plasma [206,207] and bioactive glass [179,208].

Most antimicrobials display broad effects and are not targeted to specific pathogenic species and strains. This is important, as commensal bacteria have a positive role in skin maintenance and wound repair (reviewed in [209]), and unlike their pathogenic counterparts, commensal biofilms do not cause persistent delayed healing in diabetic wounds [166]. As a result, more directed treatments for pathogenic bacteria, such as phage therapy [210] or pharmacological inhibition of bacterial virulence mechanisms such as quorum sensing [211], may confer higher specificity and efficacy. Moreover, most treatments focus on the bacterial component of infection, but the fungal diversity of wounds is also linked to healing outcome [212]. Thus, to elucidate the role of host–microorganism interactions in pathological repair, prospective research should acknowledge the wound ecosystem in its entirety.

Experimental studies are providing new insight into the underlying molecular and cellular correlates to chronic wound pathology. This in turn offers exciting new avenues for future therapeutic prevention and intervention. For example, chronic wounds are burdened by high levels of cellular senescence [141,142]. Senolytic drugs such as quercetin target senescent cells, and have already shown promise in reducing senescent cell burden in pathology [213,214] and ameliorating symptoms of diabetes, including inflammation and hyperglycaemia (reviewed in [215]). Further, blockade



of the senescence-linked receptor, CXCR2, directly accelerates diabetic wound repair *in vivo* [112]. Repurposing these existing treatments (a number of senolytic drugs and CXCR2 antagonists have been tested in clinical trials [216,217]) offers an attractive approach for wound management. Other cell-targeted strategies include the administration of stem cells (reviewed in [218]), growth factors (reviewed in [219]) and gene therapies (reviewed in [220]). The major reparative effects of emerging and potential chronic wound therapies are outlined in figure 3.

## 6. Conclusion

The high cellular diversity, complexity and plasticity of wound healing provide a considerable challenge to comprehensively elucidate. While this remains a perplexing goal, it is essential

that we continue to strive to more fully understand the mechanisms that underpin both normal and pathological healing. While not without their limitations, emerging wound models provide an unprecedented opportunity to further explore the molecular and cellular features of wound repair. Combining these approaches with novel tissue, cell and molecular 'omics' technologies will considerably advance our understanding of wound pathology. Indeed, the future holds great promise for the development of innovative new therapeutic strategies for advanced wound care.

**Data accessibility.** This article has no additional data.

**Authors' contributions.** H.N.W. wrote the manuscript. M.J.H. provided critical appraisal.

**Competing interests.** We declare we have no competing interests.

**Funding.** The authors declare no funding directly for the purpose of this publication.

## References

- Olsson M, Järbrink K, Divakar U, Bajpai R, Upton Z, Schmidtchen A, Car J. 2019 The humanistic and economic burden of chronic wounds: a systematic review. *Wound Repair Regen.* **27**, 114–125. (doi:10.1111/wrr.12683)
- Takeo M, Lee W, Ito M. 2015 Wound healing and skin regeneration. *Cold Spring Harb. Perspect. Med.* **5**, a023267. (doi:10.1101/cshperspect.a023267)
- Naik S *et al.* 2015 Commensal–dendritic-cell interaction specifies a unique protective skin immune signature. *Nature* **520**, 104–108. (doi:10.1038/nature14052)
- Broughton GI, Janis JE, Attinger CE. 2006 Wound healing: an overview. *Plast. Reconstruct. Surg.* **117**, 1e–S–32e–S. (doi:10.1097/01.prs.0000222562.60260.f9)
- Velnar T, Bailey T, Smrkolj V. 2009 The wound healing process: an overview of the cellular and molecular mechanisms. *J. Int. Med. Res.* **37**, 1528–1542. (doi:10.1177/147323000903700531)
- Golebiewska EM, Poole AW. 2015 Platelet secretion: from haemostasis to wound healing and beyond. *Blood Rev.* **29**, 153–162. (doi:10.1016/j.blre.2014.10.003)
- Zaidi A, Green L. 2019 Physiology of haemostasis. *Anaesth. Intensive Care Med.* **20**, 152–158. (doi:10.1016/j.mpaic.2019.01.005)
- Delavary BM, van der Veer WM, van Egmond M, Niessen FB, Beelen RH. 2011 Macrophages in skin injury and repair. *Immunobiology.* **216**, 753–762. (doi:10.1016/j.imbio.2011.01.001)
- Scully D *et al.* 2020 Optimising platelet secretomes to deliver robust tissue-specific regeneration. *J. Tissue Eng. Regen. Med.* **14**, 82–98. (doi:10.1002/term.2965)
- Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. 2005 Evidence of Toll-like receptor molecules on human platelets. *Immunol. Cell Biol.* **83**, 196–198. (doi:10.1111/j.1440-1711.2005.01314.x)
- Shiraki R *et al.* 2004 Expression of Toll-like receptors on human platelets. *Thromb. Res.* **113**, 379–385. (doi:10.1016/j.thromres.2004.03.023)
- Tang YQ, Yeaman MR, Selsted ME. 2002 Antimicrobial peptides from human platelets. *Infect. Immun.* **70**, 6524–6533. (doi:10.1128/iai.70.12.6524-6533.2002)
- Mann KG. 2003 Factor VII-activating protease: coagulation, fibrinolysis, and atherothrombosis? *Circulation* **107**, 654–655. (doi:10.1161/01.cir.0000057382.68508.3d)
- Kingsley K, Huff J, Rust W, Carroll K, Martinez A, Fitchmun M, Plopper GE. 2002 ERK1/2 mediates PDGF-BB stimulated vascular smooth muscle cell proliferation and migration on laminin-5. *Biochem. Biophys. Res. Commun.* **293**, 1000–1006. (doi:10.1016/S0006-291X(02)00331-5)
- Rennett RC, Sorkin M, Garg RK, Gurtner GC. 2012 Stem cell recruitment after injury: lessons for regenerative medicine. *Regen. Med.* **7**, 833–850. (doi:10.2217/rme.12.82)
- Chen L, DiPietro LA. 2017 Toll-like receptor function in acute wounds. *Adv. Wound Care* **6**, 344–355. (doi:10.1089/wound.2017.0734)
- Martin P, Leibovich SJ. 2005 Inflammatory cells during wound repair: the good, the bad and the ugly. *Trends Cell Biol.* **15**, 599–607. (doi:10.1016/j.tcb.2005.09.002)
- Vestweber D. 2015 How leukocytes cross the vascular endothelium. *Nat. Rev. Immunol.* **15**, 692–704. (doi:10.1038/nri3908)
- Subramaniam M, Saffaripour S, Van De Water L, Frenette PS, Mayadas TN, Hynes RO, Wagner DD. 1997 Role of endothelial selectins in wound repair. *Am. J. Pathol.* **150**, 1701–1709.
- Yukami T *et al.* 2007 Endothelial selectins regulate skin wound healing in cooperation with L-selectin and ICAM-1. *J. Leukoc. Biol.* **82**, 519–531. (doi:10.1189/jlb.0307152)
- Kolaczowska E, Kubes P. 2013 Neutrophil recruitment and function in health and inflammation. *Nat. Rev. Immunol.* **13**, 159–175. (doi:10.1038/nri3399)
- Segel GB, Halterman MW, Lichtman MA. 2011 The paradox of the neutrophil's role in tissue injury. *J. Leukoc. Biol.* **89**, 359–372. (doi:10.1189/jlb.0910538)
- Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. 2004 Neutrophil extracellular traps kill bacteria. *Science* **303**, 1532–1535. (doi:10.1126/science.1092385)
- Boniakowski AE, Kimball AS, Jacobs BN, Kunkel SL, Gallagher KA. 2017 Macrophage-mediated inflammation in normal and diabetic wound healing. *J. Immunol.* **199**, 17–24. (doi:10.4049/jimmunol.1700223)
- Lin Q, Fang D, Fang J, Ren X, Yang X, Wen F, Su SB. 2011 Impaired wound healing with defective expression of chemokines and recruitment of myeloid cells in TLR3-deficient mice. *J. Immunol.* **186**, 3710–3717. (doi:10.4049/jimmunol.1003007)
- Kim MH, Liu W, Borjesson DL, Curry FRE, Miller LS, Cheung AL, Liu FT, Isseroff RR, Simon, SI. 2008 Dynamics of neutrophil infiltration during cutaneous wound healing and infection using fluorescence imaging. *J. Invest. Dermatol.* **128**, 1812–1820. (doi:10.1038/sj.jid.5701223)
- Yoo SK, Huttenlocher A. 2011 Spatiotemporal photolabeling of neutrophil trafficking during inflammation in live zebrafish. *J. Leukoc. Biol.* **89**, 661–667. (doi:10.1189/jlb.1010567)
- Wang J, Hossain M, Thanabalasuriar A, Gunzer M, Meininger C, Kubes P. 2017 Visualizing the function and fate of neutrophils in sterile injury and repair. *Science* **358**, 111–116. (doi:10.1126/science.aam9690)
- Buckley CD *et al.* 2006 Identification of a phenotypically and functionally distinct population of long-lived neutrophils in a model of reverse endothelial migration. *J. Leukoc. Biol.* **79**, 303–311. (doi:10.1189/jlb.0905496)

30. Rodero MP, Licata F, Poupel L, Hamon P, Khosrotrahani K, Combadiere C, Boissonnas A. 2014 In vivo imaging reveals a pioneer wave of monocyte recruitment into mouse skin wounds. *PLoS ONE* **9**, e115508. (doi:10.1371/journal.pone.0108212)
31. Das A, Sinha M, Datta S, Abas M, Chaffee S, Sen CK, Roy S. 2015 Monocyte and macrophage plasticity in tissue repair and regeneration. *Am. J. Pathol.* **185**, 2596–2606. (doi:10.1016/j.ajpath.2015.06.001)
32. Baum CL, Arpey CJ. 2005 Normal cutaneous wound healing: clinical correlation with cellular and molecular events. *Dermatol. Surg.* **31**, 674–686. (doi:10.1111/j.1524-4725.2005.31612)
33. Mantovani A, Sica A, Locati M. 2005 Macrophage polarization comes of age. *Immunity* **23**, 344–346. (doi:10.1016/j.immuni.2005.10.001)
34. Xue J *et al.* 2014 Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity* **40**, 274–288. (doi:10.1016/j.immuni.2014.01.006)
35. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. 2014 Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* **159**, 1312–1326. (doi:10.1016/j.cell.2014.11.018)
36. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. 2016 New insights into the multidimensional concept of macrophage ontogeny, activation and function. *Nat. Immunol.* **17**, 34–40. (doi:10.1038/ni.3324)
37. Mosser DM, Edwards JP. 2008 Exploring the full spectrum of macrophage activation. *Nat. Rev. Immunol.* **8**, 958–969. (doi:10.1038/nri2448)
38. Snyder RJ, Lantis J, Kirsner RS, Shah V, Molyneaux M, Carter MJ. 2016 Macrophages: a review of their role in wound healing and their therapeutic use. *Wound Repair Regen.* **24**, 613–629. (doi:10.1111/wrr.12444)
39. Khallou-Laschet J *et al.* 2010 Macrophage plasticity in experimental atherosclerosis. *PLoS ONE* **5**, e8852. (doi:10.1371/journal.pone.0008852)
40. Das A, Ganesh K, Khanna S, Sen CK, Roy S. 2014 Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation. *J. Immunol.* **192**, 1120–1129. (doi:10.4049/jimmunol.1300613)
41. Nelson SM, Lei X, Prabhu KS. 2011 Selenium levels affect the IL-4-induced expression of alternative activation markers in murine macrophages. *J. Nutr.* **141**, 1754–1761. (doi:10.3945/jn.111.141176)
42. Lin Y-W, Lee B, Liu P-S, Wei L-N. 2016 Receptor-interacting protein 140 orchestrates the dynamics of macrophage M1/M2 polarization. *J. Innate Immun.* **8**, 97–107. (doi:10.1159/000433539)
43. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. 2008 Growth factors and cytokines in wound healing. *Wound Repair Regen.* **16**, 585–601. (doi:10.1111/j.1524-475X.2008.00410.x)
44. Eming SA, Krieg T, Davidson JM. 2007 Inflammation in wound repair: molecular and cellular mechanisms. *J. Invest. Dermatol.* **127**, 514–525. (doi:10.1038/sj.jid.5700701)
45. Campbell L, Saville CR, Murray PJ, Cruickshank SM, Hardman MJ. 2013 Local arginase 1 activity is required for cutaneous wound healing. *J. Invest. Dermatol.* **133**, 2461–2470. (doi:10.1038/jid.2013.164)
46. Jetten N, Roumans N, Gijbels MJ, Romano A, Post MJ, de Winther MP, van der Hulst RRWJ, Xanthouleas S. 2014 Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses. *PLoS ONE* **9**, e102994. (doi:10.1371/journal.pone.0102994)
47. Gurevich DB, Severn CE, Twomey C, Greenhough A, Cash J, Toye AM, Mellor H, Martin P. 2018 Live imaging of wound angiogenesis reveals macrophage orchestrated vessel sprouting and regression. *EMBO J.* **37**, e97786. (doi:10.15252/emboj.20179786)
48. Mirza R, DiPietro LA, Koh TJ. 2009 Selective and specific macrophage ablation is detrimental to wound healing in mice. *Am. J. Pathol.* **175**, 2454–2462. (doi:10.2353/ajpath.2009.090248)
49. Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Müller W, Roers A, Eming SA. 2010 Differential roles of macrophages in diverse phases of skin repair. *J. Immunol.* **184**, 3964–3977. (doi:10.4049/jimmunol.0903356)
50. Nosbaum A *et al.* 2016 Cutting edge: regulatory T cells facilitate cutaneous wound healing. *J. Immunol.* **196**, 2010–2014. (doi:10.4049/jimmunol.1502139)
51. Liu Z *et al.* 2016 Dendritic epidermal T cells facilitate wound healing in diabetic mice. *Am. J. Transl. Res.* **8**, 2375–2384.
52. Keyes BE *et al.* 2016 Impaired epidermal to dendritic T cell signaling slows wound repair in aged skin. *Cell* **167**, 1323–1338. (doi:10.1016/j.cell.2016.10.052)
53. Weller K, Foitzik K, Paus R, Syska W, Maurer M. 2006 Mast cells are required for normal healing of skin wounds in mice. *FASEB J.* **20**, 2366–2368. (doi:10.1096/fj.06-5837fje)
54. Shaw TJ, Martin P. 2016 Wound repair: a showcase for cell plasticity and migration. *Curr. Opin. Cell Biol.* **42**, 29–37. (doi:10.1016/j.celb.2016.04.001)
55. Li J, Chen J, Kirsner R. 2007 Pathophysiology of acute wound healing. *Clin. Dermatol.* **25**, 9–18. (doi:10.1016/j.clinidmatol.2006.09.007)
56. Wager LJ, Leavesley DI. 2015 MicroRNA regulation of epithelial-to-mesenchymal transition during re-epithelialisation: assessing an open wound. *Wound Pract. Res.* **23**, 132–142.
57. Thomason HA, Cooper NH, Ansell DM, Chiu M, Merritt AJ, Hardman MJ, Garrod DR. 2012 Direct evidence that PKC $\alpha$  positively regulates wound re-epithelialization: correlation with changes in desmosomal adhesiveness. *J. Pathol.* **227**, 346–356. (doi:10.1002/path.4016)
58. Nunan R, Campbell J, Mori R, Pitulescu ME, Jiang WG, Harding KG, Adams RH, Nobes CD, Martin P. 2015 Ephrin-Bs drive junctional downregulation and actin stress fiber disassembly to enable wound re-epithelialization. *Cell Rep.* **13**, 1380–1395. (doi:10.1016/j.celrep.2015.09.085)
59. Rousselle P, Braye F, Dayan G. 2019 Re-epithelialization of adult skin wounds: cellular mechanisms and therapeutic strategies. *Adv. Drug Deliv. Rev.* **146**, 344–365. (doi:10.1016/j.addr.2018.06.019)
60. Ito M, Yang Z, Andl T, Cui C, Kim N, Millar SE, Cotsarelis G. 2007 Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. *Nature* **447**, 316–320. (doi:10.1038/nature05766)
61. Ito M, Liu Y, Yang Z, Nguyen J, Liang F, Morris RJ, Cotsarelis G. 2005 Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. *Nat. Med.* **11**, 1351. (doi:10.1038/nm1328)
62. Garcin CL, Ansell DM, Headon DJ, Paus R, Hardman MJ. 2016 Hair follicle bulge stem cells appear dispensable for the acute phase of wound re-epithelialization. *Stem Cells.* **34**, 1377–1385. (doi:10.1002/stem.2289)
63. Driskell I, Oeztuerk-Winder F, Humphreys P, Frye M. 2015 Genetically induced cell death in bulge stem cells reveals their redundancy for hair and epidermal regeneration. *Stem Cells* **33**, 988–998. (doi:10.1002/stem.1910)
64. Joost S, Jacob T, Sun X, Annusver K, La Manno G, Sur I, Kasper M. 2018 Single-cell transcriptomics of traced epidermal and hair follicle stem cells reveals rapid adaptations during wound healing. *Cell Rep.* **25**, 585–597. (doi:10.1016/j.celrep.2018.09.059)
65. Santoro MM, Gaudio G. 2005 Cellular and molecular facets of keratinocyte reepithelialization during wound healing. *Exp. Cell Res.* **304**, 274–286. (doi:10.1016/j.yexcr.2004.10.033)
66. Driskell RR *et al.* 2013 Distinct fibroblast lineages determine dermal architecture in skin development and repair. *Nature* **504**, 277–281. (doi:10.1038/nature12783)
67. Sinha M *et al.* 2018 Direct conversion of injury-site myeloid cells to fibroblast-like cells of granulation tissue. *Nat. Commun.* **9**, 1–19. (doi:10.1038/s41467-018-03208-w)
68. Xue M, Jackson CJ. 2015 Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. *Adv. Wound Care* **4**, 119–136. (doi:10.1089/wound.2013.0485)
69. Huang S-P, Wu M-S, Shun C-T, Wang H-P, Hsieh C-Y, Kuo M-L, Lin J-T. 2005 Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. *J. Biomed. Sci.* **12**, 229–241. (doi:10.1007/s11373-004-8177-5)
70. Honnegowda TM, Kumar P, Udupa E, Kumar S, Kumar U, Rao P. 2015 Role of angiogenesis and angiogenic factors in acute and chronic wound healing. *Plast. Aesthet. Res.* **2**, 243–249. (doi:10.4103/2347-9264.165438)
71. Cai J, Ahmad S, Jiang WG, Huang J, Kontos CD, Boulton M, Ahmed A. 2003 Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. *Diabetes* **52**, 2959–2968. (doi:10.2337/diabetes.52.12.2959)
72. Kalebic T, Garbisa S, Glaser B, Liotta LA. 1983 Basement membrane collagen: degradation by

- migrating endothelial cells. *Science* **221**, 281–283. (doi:10.1126/science.6190230)
73. Du Cheyne C, Tay H, De Spiegelaere W. 2019 The complex TIE between macrophages and angiogenesis. *Anat. Histol. Embryol.* **49**, 585–596. (doi:10.1111/ah.12518)
  74. Willenborg S *et al.* 2012 CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. *Blood* **120**, 613–625. (doi:10.1182/blood-2012-01-403386)
  75. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozij S, Peri F, Wilson SW, Ruhrberg C. 2010 Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. *Blood* **116**, 829–840. (doi:10.1182/blood-2009-12-257832)
  76. Poché RA, Hsu C-W, McElwee ML, Burns AR, Dickinson ME. 2015 Macrophages engulf endothelial cell membrane particles preceding pupillary membrane capillary regression. *Dev. Biol.* **403**, 30–42. (doi:10.1016/j.ydbio.2015.03.017)
  77. Stefater III JA *et al.* 2011 Regulation of angiogenesis by a non-canonical Wnt–Flt1 pathway in myeloid cells. *Nature*. **474**, 511–515. (doi:10.1038/nature10085)
  78. Theocharidis G, Veves A. 2020 Autonomic nerve dysfunction and impaired diabetic wound healing: The role of neuropeptides. *Autonomic Neurosci.* **223**, 102610. (doi:10.1016/j.autneu.2019.102610)
  79. Jung N, Yu J, Um J, Dubon MJ, Park K-S. 2016 Substance P modulates properties of normal and diabetic dermal fibroblasts. *Tissue Eng. Regen. Med.* **13**, 155–161. (doi:10.1007/s13770-016-9085-2)
  80. Um J, Jung N, Chin S, Cho Y, Choi S, Park KS. 2016 Substance P enhances EPC mobilization for accelerated wound healing. *Wound Repair Regen.* **24**, 402–410. (doi:10.1111/wrr.12403)
  81. Leal EC *et al.* 2015 Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. *Am. J. Pathol.* **185**, 1638–1648. (doi:10.1016/j.ajpath.2015.02.011)
  82. Um J, Yu J, Park KS. 2017 Substance P accelerates wound healing in type 2 diabetic mice through endothelial progenitor cell mobilization and Yes-associated protein activation. *Mol. Med. Rep.* **15**, 3035–3040. (doi:10.3892/mmr.2017.6344)
  83. Zhu F-B, Fang X-J, Liu D-W, Shao Y, Zhang H-Y, Peng Y, Zhong Q, Li Y, De-ming L. 2016 Substance P combined with epidermal stem cells promotes wound healing and nerve regeneration in diabetes mellitus. *Neural Regen. Res.* **11**, 493–501. (doi:10.4103/1673-5374.179073)
  84. Parfejevs V *et al.* 2018 Injury-activated glial cells promote wound healing of the adult skin in mice. *Nat. Commun.* **9**, 1–16. (doi:10.1038/s41467-017-01488-2)
  85. Darby IA, Laverdet B, Bonté F, Desmoulière A. 2014 Fibroblasts and myofibroblasts in wound healing. *Clin. Cosmet. Investig. Dermatol.* **7**, 301–311. (doi:10.2147/CCID.S50046)
  86. Schultz GS, Wysocki A. 2009 Interactions between extracellular matrix and growth factors in wound healing. *Wound Repair Regen.* **17**, 153–162. (doi:10.1111/j.1524-475X.2009.00466.x)
  87. Witte MB, Barbul A. 1997 General principles of wound healing. *Surg. Clin. North Am.* **77**, 509–528. (doi:10.1016/s0039-6109(05)70566-1)
  88. Diegelmann RF, Evans MC. 2004 Wound healing: an overview of acute, fibrotic and delayed healing. *Front. Biosci.* **9**, 283–289. (doi:10.2741/1184)
  89. Young A, McNaught C-E. 2011 The physiology of wound healing. *Surgery* **29**, 475–479. (doi:10.1016/j.mpsur.2011.06.011)
  90. Duca L, Floquet N, Alix AJ, Haye B, Debelle L. 2004 Elastin as a matrikine. *Crit. Rev. Oncol. Hematol.* **49**, 235–244. (doi:10.1016/j.critrevonc.2003.09.007)
  91. Almine JF, Wise SG, Weiss AS. 2012 Elastin signaling in wound repair. *Birth Defects Res. C Embryo Today.* **96**, 248–257. (doi:10.1002/bdrc.21016)
  92. Amadeu TP, Braune AS, Porto LC, Desmoulière A, Costa AM. 2004 Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids. *Wound Repair Regen.* **12**, 169–174. (doi:10.1111/j.1067-1927.2004.012209.x)
  93. Hinz B, Mastrangelo D, Iselin CE, Chaponnier C, Gabbiani G. 2001 Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. *Am. J. Pathol.* **159**, 1009–1020. (doi:10.1016/S0002-9440(10)61776-2)
  94. Tomasek JJ, Haaksma CJ, Schwartz RJ, Howard EW. 2013 Whole animal knockout of smooth muscle alpha-actin does not alter excisional wound healing or the fibroblast-to-myofibroblast transition. *Wound Repair Regen.* **21**, 166–176. (doi:10.1111/wrr.12001)
  95. Stadelmann WK, Digenis AG, Tobin GR. 1998 Physiology and healing dynamics of chronic cutaneous wounds. *Am. J. Surg.* **176**, 265–385. (doi:10.1016/S0002-9610(98)00183-4)
  96. Larouche J, Sheoran S, Maruyama K, Martino MM. 2018 Immune regulation of skin wound healing: mechanisms and novel therapeutic targets. *Adv. Wound Care* **7**, 209–231. (doi:10.1089/wound.2017.0761)
  97. Werner S, Grose R. 2003 Regulation of wound healing by growth factors and cytokines. *Physiol. Rev.* **83**, 835–870. (doi:10.1152/physrev.2003.83.3.835)
  98. Hartenstein B, Dittrich BT, Stickens D, Heyer B, Vu TH, Teurich S, Schorpp-Kistner M, Werb Z, Angel P. 2006 Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice. *J. Invest. Dermatol.* **126**, 486–496. (doi:10.1038/sj.jid.5700084)
  99. Guo L, Degenstein L, Fuchs E. 1996 Keratinocyte growth factor is required for hair development but not for wound healing. *Genes Dev.* **10**, 165–175. (doi:10.1101/gad.10.2.165)
  100. Luetette NC, Qiu TH, Peiffer RL, Oliver P, Smithies O, Lee DC. 1993 TGF $\alpha$  deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. *Cell*. **73**, 263–278. (doi:10.1016/0092-8674(93)90228-1)
  101. Tsou R, Fathke C, Wilson L, Wallace K, Gibran N, Isik F. 2002 Retroviral delivery of dominant-negative vascular endothelial growth factor receptor type 2 to murine wounds inhibits wound angiogenesis. *Wound Repair Regen.* **10**, 222–229. (doi:10.1046/j.1524-475x.2002.10405.x)
  102. Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, Vowden K, Vowden P. 2015 Health economic burden that wounds impose on the National Health Service in the UK. *BMJ Open* **5**, e009283. (doi:10.1136/bmjopen-2015-009283)
  103. Lindholm C, Searle R. 2016 Wound management for the 21st century: combining effectiveness and efficiency. *Int. Wound J.* **13**, 5–15. (doi:10.1111/iwj.12623)
  104. Alavi A *et al.* 2014 Diabetic foot ulcers: Part I. Pathophysiology and prevention. *J. Am. Acad. Dermatol.* **70**, 1. (doi:10.1016/j.jaad.2013.06.055)
  105. Park HY, Kim JH, Jung M, Chung CH, Hasham R, Park CS, Choi EH. 2011 A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process. *Exp. Dermatol.* **20**, 969–974. (doi:10.1111/j.1600-0625.2011.01364.x)
  106. Seyfarth F, Schliemann S, Antonov D, Elsner P. 2011 Dry skin, barrier function, and irritant contact dermatitis in the elderly. *Clin. Dermatol.* **29**, 31–36. (doi:10.1016/j.cindermatol.2010.07.004)
  107. Bermudez DM, Herdrich BJ, Xu J, Lind R, Beason DP, Mitchell ME, Soslowsky LJ, Liechty KW. 2011 Impaired biomechanical properties of diabetic skin: implications in pathogenesis of diabetic wound complications. *Am. J. Pathol.* **178**, 2215–2223. (doi:10.1016/j.ajpath.2011.01.015)
  108. Diridollou S, Vabre V, Berson M, Vaillant L, Black D, Lagarde JM, Grégoire JM, Gall Y, Patat F. 2001 Skin ageing: changes of physical properties of human skin *in vivo*. *Int. J. Cosmet. Sci.* **23**, 353–362. (doi:10.1046/j.0412-5463.2001.00105.x)
  109. Wilkinson HN, Hardman MJ. In press. Wound senescence: a functional link between diabetes and ageing? *Exp. Dermatol.* (doi:10.1111/exd.14082)
  110. Childs BG, Durik M, Baker DJ, Van Deursen JM. 2015 Cellular senescence in aging and age-related disease: from mechanisms to therapy. *Nat. Med.* **21**, 1424. (doi:10.1038/nm.4000)
  111. Nelson G, Kucheryavenko O, Wordsworth J, von Zglinicki T. 2018 The senescent bystander effect is caused by ROS-activated NF- $\kappa$ B signalling. *Mech. Ageing Dev.* **170**, 30–36. (doi:10.1016/j.mad.2017.08.005)
  112. Wilkinson HN, Clowes C, Banyard KL, Matteuci P, Mace KA, Hardman MJ. 2019 Elevated local senescence in diabetic wound healing is linked to pathological repair via CXCR2. *J. Invest. Dermatol.* **139**, 1171–1181. (doi:10.1016/j.jid.2019.01.005)
  113. Galkowska H, Olszewski WL, Wojewodzka U. 2005 Expression of natural antimicrobial peptide  $\beta$ -defensin-2 and Langerhans cell accumulation in epidermis from human non-healing leg ulcers. *Folia Histochem. Cytobiol.* **43**, 133–136.
  114. Stojadinovic O, Yin N, Lehmann J, Pastar I, Kirsner RS, Tomic-Canic M. 2013 Increased number of Langerhans cells in the epidermis of diabetic foot ulcers correlates with healing outcome. *Immunologic research* **57**, 222–228. (doi:10.1007/s12026-013-8474-z)
  115. Diegelmann RF. 2003 Excessive neutrophils characterize chronic pressure ulcers. *Wound Rep. Regen.* **11**, 490–495. (doi:10.1046/j.1524-475X.2003.11617.x)



116. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. 1998 Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. *J. Invest. Dermatol.* **111**, 850–857. (doi:10.1046/j.1523-1747.1998.00381.x)
117. Sindrilaru A *et al.* 2011 An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. *J. Clin. Invest.* **121**, 985–997. (doi:10.1172/JCI44490)
118. Bullen EC, Longaker MT, Uptide DL, Benton R, Ladin D, Hou Z, Howard EW. 1995 Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. *J. Invest. Dermatol.* **104**, 236–240.
119. Trengove NJ, Stacey MC, Macauley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G. 1999 Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. *Wound Repair Regen.* **7**, 442–452. (doi:10.1046/j.1524-475x.1999.00442.x)
120. Wysocki AB, Staiano-Coico L, Grinnell F. 1993 Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. *J. Invest. Dermatol.* **101**, 64–68. (doi:10.1111/1523-1747.ep12359590)
121. Rayment EA, Upton Z, Shooter GK. 2008 Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. *Brit. J. Dermatol.* **158**, 951–961. (doi:10.1111/j.1365-2133.2008.08462.x)
122. Wetzler C, Kämpfer H, Stallmeyer B, Pfeilschifter J, Frank S. 2000 Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. *J. Invest. Dermatol.* **115**, 245–253. (doi:10.1046/j.1523-1747.2000.00029.x)
123. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, Lohmeyer J, Preissner KT. 2012 Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. *PLoS ONE* **7**, e32366. (doi:10.1371/journal.pone.0032366)
124. Wong SL, Demers M, Martinod K, Gallant M, Wang Y, Goldfine AB, Kahn CR, Wagner DD. 2015 Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. *Nat. Med.* **21**, 815–819. (doi:10.1038/nm.3887)
125. Hanses F, Park S, Rich J, Lee JC. 2011 Reduced neutrophil apoptosis in diabetic mice during staphylococcal infection leads to prolonged Tnf $\alpha$  production and reduced neutrophil clearance. *PLoS ONE* **6**, e23633. (doi:10.1371/journal.pone.0023633)
126. Khanna S *et al.* 2010 Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. *PLoS ONE* **5**, e9539. (doi:10.1371/journal.pone.0009539)
127. Lecube A, Pachón G, Petriz J, Hernández C, Simó R. 2011 Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. *PLoS ONE* **6**, e23366. (doi:10.1371/journal.pone.0023366)
128. Pettersson US, Christofferson G, Massena S, Ahl D, Jansson L, Henriksnäs J, Phillipson M. 2011 Increased recruitment but impaired function of leukocytes during inflammation in mouse models of type 1 and type 2 diabetes. *PLoS ONE* **6**, 22480. (doi:10.1371/journal.pone.0022480)
129. Bannon P, Wood S, Restivo T, Campbell L, Hardman MJ, Mace KA. 2013 Diabetes induces stable intrinsic changes to myeloid cells that contribute to chronic inflammation during wound healing in mice. *Dis. Model. Mech.* **6**, 1434–1447. (doi:10.1242/dmm.012237)
130. Tellechea A *et al.* 2016 Mast cells regulate wound healing in diabetes. *Diabetes* **65**, 2006–2019. (doi:10.2337/db15-0340)
131. Moura J, Rodrigues J, Gonçalves M, Amaral C, Lima M, Carvalho E. 2017 Impaired T-cell differentiation in diabetic foot ulceration. *Cell. Mol. Immunol.* **14**, 758–769. (doi:10.1038/cmi.2015)
132. Stojadinovic O, Brem H, Vouthounis C, Lee B, Fallon J, Stallcup M, Merchant A, Galiano RD, Tomic-Canic M. 2005 Molecular pathogenesis of chronic wounds: the role of  $\beta$ -catenin and c-myc in the inhibition of epithelialization and wound healing. *Am. J. Pathol.* **167**, 59–69. (doi:10.1016/s0002-9440(10)62953-7)
133. Waikel RL, Kawachi Y, Waikel PA, Wang X-J, Roop DR. 2001 Deregulated expression of c-Myc depletes epidermal stem cells. *Nat. Genet.* **28**, 165–168. (doi:10.1038/88889)
134. Stojadinovic O, Pastar I, Vukelic S, Mahoney MG, Brennan D, Krzyzanowska A, Golinko M, Brem H, Tomic-Canic M. 2008 Deregulation of keratinocyte differentiation and activation: a hallmark of venous ulcers. *J. Cell. Mol. Med.* **12**, 2675–2690. (doi:10.1111/j.1582-4934.2008.00321.x)
135. Pastar I, Stojadinovic O, Krzyzanowska A, Barrientos S, Stuelten C, Zimmerman K, Blumenberg M, Brem H, Tomic-Canic M. 2010 Attenuation of the transforming growth factor beta-signaling pathway in chronic venous ulcers. *Mol. Med.* **16**, 92–101. (doi:10.2119/molmed.2009.00149)
136. Stojadinovic O, Pastar I, Nusbaum AG, Vukelic S, Krzyzanowska A, Tomic-Canic M. 2014 Deregulation of epidermal stem cell niche contributes to pathogenesis of nonhealing venous ulcers. *Wound Repair Regen.* **22**, 220–227. (doi:10.1111/wrr.12142)
137. Lauer G, Sollberg S, Cole M, Flamme I, Stürzebecher J, Mann K, Krieg T, Eming SA. 2000 Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. *J. Invest. Dermatol.* **115**, 12–18. (doi:10.1046/j.1523-1747.2000.00036.x)
138. Yager DR, Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Kelman Cohen I. 1997 Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. *Wound Repair Regen.* **5**, 23–32. (doi:10.1046/j.1524-475x.1997.50108.x)
139. Wallace HJ, Stacey MC. 1998 Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers: correlations to healing status. *J. Invest. Dermatol.* **110**, 292–296. (doi:10.1046/j.1523-1747.1998.00113.x)
140. Stephens P *et al.* 2003 An analysis of replicative senescence in dermal fibroblasts derived from chronic leg wounds predicts that telomerase therapy would fail to reverse their disease-specific cellular and proteolytic phenotype. *Exp. Cell Res.* **283**, 22–35. (doi:10.1016/s0014-4827(02)00021-6)
141. Wall IB, Moseley R, Baird DM, Kipling D, Giles P, Laffanian I, Price PE, Thomas DW, Stephens P. 2008 Fibroblast dysfunction is a key factor in the non-healing of chronic venous leg ulcers. *J. Invest. Dermatol.* **128**, 2526–2540. (doi:10.1038/jid.2008.114)
142. Vande BJS, Rudolph R, Hollan C, Haywood-Reid PL. 1998 Fibroblast senescence in pressure ulcers. *Wound Repair Regen.* **6**, 38–49. (doi:10.1046/j.1524-475x.1998.60107.x)
143. Kim BC, Kim HT, Park SH, Cha JS, Yufit T, Kim SJ, Falanga V. 2003 Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression. *J. Cell. Physiol.* **195**, 331–336. (doi:10.1002/jcp.10301)
144. Hasan A, Murata H, Falabella A, Ochoa S, Zhou L, Badiavas E, Falanga V. 1997 Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. *J. Dermatol. Sci.* **16**, 59–66. (doi:10.1016/s0923-1811(97)00622-1)
145. Wilkinson HN, Upson SE, Banyard KL, Knight R, Mace KA, Hardman MJ. 2019 Reduced iron in diabetic wounds: An oxidative stress-dependent role for STEAP3 in extracellular matrix deposition and remodeling. *J. Invest. Dermatol.* **139**, 2368–2377. (doi:10.1016/j.jid.2019.05.014)
146. Wilkinson HN, Roberts ER, Stafford AR, Banyard KL, Matteucci P, Mace KA, Hardman MJ. 2019 Tissue iron promotes wound repair via m2 macrophage polarization and the chemokine (cc motif) ligands 17 and 22. *Am. J. Pathol.* **189**, 2196–2208. (doi:10.1016/j.ajpath.2019.07.015)
147. Duscher D *et al.* 2015 Transdermal deferoxamine prevents pressure-induced diabetic ulcers. *Proc. Natl. Acad. Sci. USA* **112**, 94–99. (doi:10.1073/pnas.1413445112)
148. Bonham CA, Rodrigues M, Galvez M, Trotsyuk A, Stern-Buchbinder Z, Inayathullah M, Rajadas J, Gurtner GC. 2018 Deferoxamine can prevent pressure ulcers and accelerate healing in aged mice. *Wound Repair Regen.* **26**, 300–305. (doi:10.1111/wrr.12667)
149. Stegenga ME *et al.* 2008 Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. *Diabet. Med.* **25**, 157–164. (doi:10.1111/j.1464-5491.2007.02348.x)
150. Prattichizzo F *et al.* 2018 Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. *Redox Biol.* **15**, 170–181. (doi:10.1016/j.redox.2017.12.001)
151. Gkogkolou P, Böhm M. 2010 Advanced glycation end products: key players in skin aging? *Dermato-*

- endocrinology*. **4**, 259–270. (doi:10.4161/derm.22028)
152. Ramasamy R, Yan SF, Schmidt AM. 2011 Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications. *Ann. N. Y. Acad. Sci.* **1243**, 88–102. (doi:10.1111/j.1749-6632.2011.06320.x)
  153. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, Nedeau A, Thom SR, Velazquez OC. 2007 Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. *J. Clin. Invest.* **117**, 1249–1259. (doi:10.1172/JCI29710)
  154. Thangarajah H *et al.* 2009 The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. *Proc. Natl Acad. Sci. USA* **106**, 13 505–13 510. (doi:10.1073/pnas.0906670106)
  155. Walsh J, Hoffstad O, Sullivan M, Margolis D. 2016 Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. *Diabet. Med.* **33**, 1493–1498. (doi:10.1111/dme.13054)
  156. Januszky M *et al.* 2014 Diabetes irreversibly depletes bone marrow-derived mesenchymal progenitor cell subpopulations. *Diabetes* **63**, 3047–3056. (doi:10.2337/db13-1366)
  157. Rennert RC *et al.* 2014 Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. *Stem Cell Res. Ther.* **5**, 79. (doi:10.1186/scrt468)
  158. Whittam AJ *et al.* 2019 Small molecule inhibition of dipeptidyl peptidase-4 enhances bone marrow progenitor cell function and angiogenesis in diabetic wounds. *Transl. Res.* **205**, 51–63. (doi:10.1016/j.trsl.2018.10.006)
  159. Vulesevic B *et al.* 2014 Glyoxalase-1 overexpression in bone marrow cells reverses defective neovascularization in STZ-induced diabetic mice. *Cardiovasc. Res.* **101**, 306–316. (doi:10.1093/cvr/cvt259)
  160. Harding K, Morris H, Patel G. 2002 Science, medicine, and the future: healing chronic wounds. *Brit. Med. J.* **324**, 160–163. (doi:10.1136/bmj.324.7330.160)
  161. Pierce GF *et al.* 1995 Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. *J. Clin. Invest.* **96**, 1336–1350. (doi:10.1172/JCI118169)
  162. Han G, Ceilley R. 2017 Chronic wound healing: a review of current management and treatments. *Adv. Ther.* **34**, 599–610. (doi:10.1007/s12325-017-0478-y)
  163. Basu S, Panray TR, Singh TB, Gulati AK, Shukla VK. 2009 A prospective, descriptive study to identify the microbiological profile of chronic wounds in outpatients. *Ostomy Wound Manage.* **55**, 14–20.
  164. Kalan LR, Meisel JS, Loesche MA, Horwinski J, Soaita I, Chen X, Uberoi A, Gardner SE, Grice EA. 2019 Strain- and species-level variation in the microbiome of diabetic wounds is associated with clinical outcomes and therapeutic efficacy. *Cell Host Microbe*. **25**, 641–655. (doi:10.1016/j.chom.2019.03.006)
  165. Loesche M *et al.* 2017 Temporal stability in chronic wound microbiota is associated with poor healing. *J. Invest. Dermatol.* **137**, 237–244. (doi:10.1016/j.jid.2016.08.009)
  166. Clinton A, Carter T. 2015 Chronic wound biofilms: Pathogenesis and potential therapies. *Lab. Med.* **46**, 277–284. (doi:10.1309/LMBNSWKUI4JPN750)
  167. Kim HJ *et al.* 2019 Segregation of age-related skin microbiome characteristics by functionality. *Sci Rep.* **9**, 1–11. (doi:10.1038/s41598-019-53266-3)
  168. Gardiner M, Vicaretti M, Sparks J, Bansal S, Bush S, Liu M, Darling A, Harry E, Burke CM. 2017 A longitudinal study of the diabetic skin and wound microbiome. *PeerJ.* **5**, e3543. (doi:10.7717/peerj.3543)
  169. Dasu MR, Martin SJ. 2014 Toll-like receptor expression and signaling in human diabetic wounds. *World J. Diabetes.* **5**, 219–223. (doi:10.4239/wjdv.v5.i2.219)
  170. Campbell L, Williams H, Crompton RA, Cruickshank SM, Hardman MJ. 2013 Nod2 deficiency impairs inflammatory and epithelial aspects of the cutaneous wound-healing response. *J. Pathol.* **229**, 121–131. (doi:10.1002/path.4095)
  171. Williams H, Crompton RA, Thomason HA, Campbell L, Singh G, McBain AJ, Cruickshank SM, Hardman MJ. 2017 Cutaneous Nod2 expression regulates the skin microbiome and wound healing in a murine model. *J. Invest. Dermatol.* **137**, 2427–2436. (doi:10.1016/j.jid.2017.05.029)
  172. Didelot X, Bowden R, Wilson DJ, Peto TEA, Crook DW. 2012 Transforming clinical microbiology with bacterial genome sequencing. *Nat. Rev. Genet.* **13**, 601–612. (doi:10.1038/nrg3226)
  173. Johnson JS *et al.* 2019 Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis. *Nat. Commun.* **10**, 5029. (doi:10.1038/s41467-019-13036-1)
  174. Ashton PM, Nair S, Dallman T, Rubino S, Rabsch W, Mwaigwisya S, Wain J, O'Grady J. 2015 MinION nanopore sequencing identifies the position and structure of a bacterial antibiotic resistance island. *Nat. Biotechnol.* **33**, 296–300. (doi:10.1038/nbt.3103)
  175. Itoh M, Umegaki-Arao N, Guo Z, Liu L, Higgins CA, Christiano AM. 2013 Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs). *PLoS ONE* **8**, e77673. (doi:10.1371/journal.pone.0077673)
  176. Kuo S, Kim HM, Wang Z, Bingham EL, Miyazawa A, Marcelo CL, Feinberg SE. 2018 Comparison of two decellularized dermal equivalents. *J. Tissue Eng. Regen. Med.* **12**, 983–990. (doi:10.1002/term.2530)
  177. Mazio C, Casale C, Imperato G, Urciuolo F, Attanasio C, De Gregorio M, Rescigno F, Netti PA. 2019 Pre-vascularized dermis model for fast and functional anastomosis with host vasculature. *Biomaterials*. **192**, 159–170. (doi:10.1016/j.biomaterials.2018.11.018)
  178. Kim BS, Gao G, Kim JY, Cho DW. 2019 3D cell printing of perfusable vascularized human skin equivalent composed of epidermis, dermis, and hypodermis for better structural recapitulation of native skin. *Adv. Healthcare Mater.* **8**, 1801019. (doi:10.1002/adhm.201801019)
  179. Wilkinson H, Iveson S, Catherall P, Hardman M. 2018 A novel silver bioactive glass elicits antimicrobial efficacy against *Pseudomonas aeruginosa* and *Staphylococcus aureus* in an ex vivo skin wound biofilm model. *Front. Microbiol.* **9**, 1450. (doi:10.3389/fmicb.2018.01450)
  180. Ueck C *et al.* 2017 Comparison of in-vitro and ex-vivo wound healing assays for the investigation of diabetic wound healing and demonstration of a beneficial effect of a triterpene extract. *PLoS ONE* **12**, e0169028. (doi:10.1371/journal.pone.0169028)
  181. Zhou L, Zhang X, Paus R, Lu Z. 2018 The renaissance of human skin organ culture: A critical reappraisal. *Differentiation* **104**, 22–35. (doi:10.1016/j.diff.2018.10.002)
  182. Ataç B, Wagner I, Horland R, Lauster R, Marx U, Tonevitsky AG, Azar RP, Lindner G. 2013 Skin and hair on-a-chip: in vitro skin models versus ex vivo tissue maintenance with dynamic perfusion. *Lab Chip*. **13**, 3555–3561. (doi:10.1039/c3lc50227a)
  183. Godin B, Touitou E. 2007 Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. *Adv. Drug Deliv. Rev.* **59**, 1152–1161. (doi:10.1016/j.addr.2007.07.004)
  184. Ansell DM, Holden KA, Hardman MJ. 2012 Animal models of wound repair: are they cutting it? *Exp. Dermatol.* **21**, 581–585. (doi:10.1111/j.1600-0625.2012.01540.x)
  185. Hancı V, Hakimoğlu S, Özçmak H, Bektaş S, Özçmak HS, Özdamar ŞO, Yurtlu S, Turan İÖ. 2012 Comparison of the effects of bupivacaine, lidocaine, and tramadol infiltration on wound healing in rats. *Rev. Bras. Anestesiol.* **62**, 804–810. (doi:10.1016/S0034-7094(12)70180-0)
  186. Strong AL, Bowles AC, MacCrimmon CP, Lee SJ, Frazier TP, Katz AJ, Gawronska-Kozak B, Bunnell BA, Gimble JM. 2015 Characterization of a murine pressure ulcer model to assess efficacy of adipose-derived stromal cells. *Plast. Reconstr. Surg.* **3**, e334. (doi:10.1097/GOX.0000000000000260)
  187. Hirsch T *et al.* 2008 Enhanced susceptibility to infections in a diabetic wound healing model. *BMC Surg.* **8**, 1–8. (doi:10.1186/1471-2482-8-5)
  188. Roper JA, Williamson RC, Bally B, Cowell CA, Brooks R, Stephens P, Harrison AJ, Bass MD. 2015 Ultrasonic stimulation of mouse skin reverses the healing delays in diabetes and aging by activation of Rac1. *J. Invest. Dermatol.* **135**, 2842–2285. (doi:10.1038/jid.2015.224)
  189. Blecher K *et al.* 2012 Nitric oxide-releasing nanoparticles accelerate wound healing in NOD-SCID mice. *Nanomedicine*. **8**, 1364–1371. (doi:10.1016/j.nano.2012.02.014)
  190. Hozzein WN, Badr G, Al Ghamdi AA, Sayed A, Al-Waili NS, Garraud O. 2015 Topical application of propolis enhances cutaneous wound healing by promoting TGF-beta/Smad-mediated collagen production in a streptozotocin-induced type I diabetic mouse model. *Cell. Physiol. Biochem.* **37**, 940–954. (doi:10.1159/000430221)

191. Long M *et al.* 2016 An essential role of NRF2 in diabetic wound healing. *Diabetes* **65**, 780–793. (doi:10.2337/db15-0564)
192. Ansell DM, Marsh C, Walker L, Hardman MJ, Holden K. 2018 Evaluating STZ-induced impaired wound healing in rats. *J. Invest. Dermatol.* **138**, 994–997. (doi:10.1016/j.jid.2017.10.020)
193. O'Brien PD, Sakowski SA, Feldman EL. 2014 Mouse models of diabetic neuropathy. *ILAR J.* **54**, 259–272. (doi:10.1093/ilar/ilt052)
194. Seitz O, Schürmann C, Hermes N, Müller E, Pfeilschifter J, Frank S, Goren I. 2010 Wound healing in mice with high-fat diet-or ob gene-induced diabetes-obesity syndromes: a comparative study. *Exp. Diab. Res.* **2011**, 476969. (doi: 10.1155/2010/476969)
195. Kim DJ, Mustoe T, Clark RA. 2015 Cutaneous wound healing in aging small mammals: a systematic review. *Wound Repair Regen.* **23**, 318–339. (doi:10.1111/wrr.12290)
196. Han N-R, Kim H-Y, Yang WM, Jeong H-J, Kim H-M. 2015 Glutamic acid ameliorates estrogen deficiency-induced menopausal-like symptoms in ovariectomized mice. *Nutr. Res.* **35**, 774–783. (doi:10.1016/j.nutres.2015.06.006)
197. Wilkinson HN, Hardman MJ. 2017 The role of estrogen in cutaneous ageing and repair. *Maturitas.* **103**, 60–64. (doi:10.1016/j.maturitas.2017.06.026)
198. Makrantonaki E, Wlaschek M, Scharffetter-Kochanek K. 2017 Pathogenesis of wound healing disorders in the elderly. *J. Dtsch. Dermatol. Ges.* **15**, 255–275. (doi:10.1111/ddg.13199)
199. Wilkinson HN, McBain AJ, Stephenson C, Hardman MJ. 2016 Comparing the effectiveness of polymer debriding devices using a porcine wound biofilm model. *Adv. Wound Care.* **5**, 475–485. (doi:10.1089/wound.2015.0683)
200. Stephen-Haynes J, Thompson G. 2007 The different methods of wound debridement. *Br. J. Community Nurs.* **12**, S6–S16.
201. Fonder MA, Lazarus GS, Cowan DA, Aronson-Cook B, Kohli AR, Mamelak AJ. 2008 Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. *J. Am. Acad. Dermatol.* **58**, 185–206. (doi:10.1016/j.jaad.2007.08.048)
202. Baltzis D, Eleftheriadou I, Veves A. 2014 Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. *Adv. Ther.* **31**, 817–836. (doi:10.1007/s12325-014-0140-x)
203. Skórkowska-Telichowska K, Czemplik M, Kulma A, Szopa J. 2013 The local treatment and available dressings designed for chronic wounds. *J. Am. Acad. Dermatol.* **68**, e117–ee26. (doi:10.1016/j.jaad.2011.06.028)
204. Brownhill VR, Huddleston E, Bell A, Hart J, Webster I, Hardman MJ, Wilkinson HN. In press. Pre-clinical assessment of single-use negative pressure wound therapy during *in vivo* porcine wound healing. *Adv. Wound Care.* (doi:10.1089/wound.2020.1218)
205. Konop M, Damps T, Misicka A, Rudnicka L. 2016 Certain aspects of silver and silver nanoparticles in wound care: a minireview. *J. Nanomater.* **2016**, 7614753. (doi:10.1155/2016/7614753)
206. Arndt S, Unger P, Berneburg M, Bosserhoff AK, Karrer S. 2018 Cold atmospheric plasma (CAP) activates angiogenesis-related molecules in skin keratinocytes, fibroblasts and endothelial cells and improves wound angiogenesis in an autocrine and paracrine mode. *J. Dermatol. Sci.* **89**, 181–190. (doi:10.1016/j.jdermsci.2017.11.008)
207. Isbary G *et al.* 2010 A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients. *Br. J. Dermatol.* **163**, 78–82. (doi:10.1111/j.1365-2133.2010.09744.x)
208. Xie W, Fu X, Tang F, Mo Y, Cheng J, Wang H, Chen X. 2019 Dose-dependent modulation effects of bioactive glass particles on macrophages and diabetic wound healing. *J. Mater. Chem. B.* **7**, 940–952. (doi:10.1039/C8TB02938E)
209. Lukic J, Chen V, Strahinic I, Begovic J, Lev-Tov H, Davis SC, Tomic-Canic M, Pastar I. 2017 Probiotics or pro-healers: The role of beneficial bacteria in tissue repair. *Wound Repair Regen.* **25**, 912–922. (doi:10.1111/wrr.12607)
210. El-Shibiny A, El-Sahhar S. 2017 Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria. *Can. J. Microbiol.* **63**, 865–879. (doi:10.1139/cjm-2017-0030)
211. Johnson BK, Abramovitch RB. 2017 Small molecules that sabotage bacterial virulence. *Trends Pharmacol. Sci.* **38**, 339–362. (doi:10.1016/j.tips.2017.01.004)
212. Kalan L, Loesche M, Hodkinson BP, Heilmann K, Ruthel G, Gardner SE, Grice EA. 2016 Redefining the chronic-wound microbiome: fungal communities are prevalent, dynamic, and associated with delayed healing. *mBio.* **7**, e01058-16. (doi:10.1128/mBio.01058-16)
213. Hickson LJ *et al.* 2019 Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine* **47**, 446–456. (doi:10.1016/j.ebiom.2019.08.069)
214. Hohmann MS, Habel DM, Coelho AL, Verri WA, Hogaboam CM. 2019 Quercetin enhances ligand-induced apoptosis in senescent idiopathic pulmonary fibrosis fibroblasts and reduces lung fibrosis *in vivo*. *Am. J. Respir. Cell Mol. Biol.* **60**, 28–40. (doi:10.1165/rcmb.2017-02890C)
215. Chen S, Jiang H, Wu X, Fang J. 2016 Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes. *Mediators Inflamm.* **2016**, 9340637. (doi:10.1155/2016/9340637)
216. Han MK, Barreto TA, Martinez FJ, Comstock AT, Sajjan US. 2020 Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. *BMJ Open Respir. Res.* **7**, e000392. (doi:10.1136/bmjresp-2018-000392)
217. Rennard SI *et al.* 2015 CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **191**, 1001–1011. (doi:10.1164/rccm.201405-0992OC)
218. Kucharzewski M, Rojczyk E, Wilemska-Kucharzewska K, Wilk R, Hudecki J, Los MJ. 2019 Novel trends in application of stem cells in skin wound healing. *Eur. J. Pharmacol.* **843**, 307–315. (doi:10.1016/j.ejphar.2018.12.012)
219. Rao SS, Venkatesan J, Prabhu A, Rekha PD. 2020 Natural polymeric biomaterials in growth factor delivery for treating diabetic foot ulcers. *J. Drug Deliv. Sci. Technol.* **55**, 101385. (doi:10.1016/j.jddst.2019.101385)
220. Veith AP, Henderson K, Spencer A, Sligar AD, Baker AB. 2019 Therapeutic strategies for enhancing angiogenesis in wound healing. *Adv. Drug Deliv. Rev.* **146**, 97–125. (doi:10.1016/j.addr.2018.09.010)